NCT01084551 - Study of SPM 962 in Patients With Restless Legs Syndrome (RLS) | Biotech Hunter

Enrollment

284

Participants

Timeline

Start Date

February 28, 2010

Primary Completion Date

September 30, 2011

Study Completion Date

September 30, 2011

Conditions

Idiopathic Restless Legs Syndrome

Interventions

DRUG

SPM 962

once a daily transdermal administration started at 2.25 mg/day to 4.5 mg/day for 13 weeks

DRUG

SPM 962

once a daily transdermal administration started at 2.25 mg/day to 6.75 mg/day for 13 weeks

DRUG

Placebo of SPM 962

once a daily transdermal administration for 13 weeks

Trial Locations (8)

Chubu Region

Chugoku Region

Hokkaido Region

Kansai Region

Kanto Region

Kyushu Region

Shikoku Region

Tohoku Region